89Zr-anti-γH2AX-TAT allows early monitoring of response to gemcitabine and capecitabine therapy in pancreatic ductal adenocarcinoma

Knight J., Mosley M., Constreas Bravo L., Fokas E., Cornelissen B.

Type

Conference paper

Publisher

Journal of Nuclear Medicine

Publication Date

01/05/2016

Volume

57

Pages

333 - 333

Permalink